Introduction {#s1}
============

The release of neutrophil extracellular traps (NETs), first reported in 2004 (Brinkmann, [@B18]), is one of the anti-microbial actions of neutrophils. NETs are mesh-like structures that contain DNA as a backbone, with anti-microbial proteins attached (Amulic and Hayes, [@B4]). NETs trap microbes and form an anti-microbial-protein-rich microenvironment (Medina, [@B80]).

Pentraxin 3 (PTX3) was reported as one of the NET component proteins (Jaillon et al., [@B58]). PTX3 is a member of pentraxin family and mainly acts as a soluble pattern recognition receptor (PRR) in the innate immune response (Bottazzi et al., [@B14]). In NETs, PTX3 may participate in microbial recognition by facilitating the trapping of microbes. The circulating PTX3 level is known to be increased in certain diseases, and PTX3 may predominantly play a critical role in host protection. Interestingly, proteomic identification of the circulating PTX3 interacting proteins revealed that PTX3 formed a complex with NET component proteins (Daigo et al., [@B26]). This finding implies that the NET component proteins are active in pathogen recognition and clearance by tethering with each other in NETs and bloodstream. PTX3 appears to be a key tethering molecule to enhance the actions of NETs component proteins. In this review, we will discuss the host-protective roles of PTX3 in relation to NETs component proteins.

NETs
====

Source, expression, and function
--------------------------------

Neutrophils are the major player in the innate immune system response against microbial pathogen invasion. One of the anti-microbial activities of neutrophils is the extrusion of NETs (Brinkmann, [@B18]). NETs are formed upon the activation of neutrophils by factors such as IL-8, lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate (PMA), bacteria, fungi, and activated platelets (Brinkmann, [@B18]; Clark et al., [@B25]; Fuchs et al., [@B37]). Neutrophil death as a result of the extrusion of NETs is called "NETosis," which is a cell death pathway distinct from apoptosis or necrosis (Brinkmann and Zychlinsky, [@B19]; Steinberg and Grinstein, [@B112]). The release of NETs has also been reportedly observed without cell death (Yipp et al., [@B123]). Extracellular formations of this type are also observed in basophils and eosinophils (Schorn et al., [@B106]). NETs are mesh-like structures that consist of cellular DNA, along with bactericidal proteins, that reside in neutrophil granules and the nucleus. These proteins are connected to DNA fibers, and form a specialized microenvironment which facilitates the capture and killing of bacteria.

The NET component proteins
--------------------------

Using a proteomic approach, Urban et al. identified 24 NET-associated proteins (Urban et al., [@B116]). These proteins are; nuclear components such as core histones; granular components such as neutrophil elastase (ELANE), lactotransferrin (LTF), cathepsin G (CTSG), myeloperoxidase (MPO), proteinase 3 (PRTN3), azurocidin 1 (AZU1), lysozyme C (LYZ), neutrophil defensins, and cytoplasmic proteins. In other proteins, histone H1, bactericidal permeability-increasing protein (BPI), pentraxin 3 (PTX3), and cathelicidin anti-microbial peptide (CAMP) are also defined as NET component proteins (Brinkmann, [@B18]; Jaillon et al., [@B58]; Lauth et al., [@B68]). Essentially all of these proteins possess anti-microbial activity.

PTX3
====

Genome
------

Breviario et al. identified PTX3 as one of the IL-1β -induced genes in human umbilical vein endothelial cells (HUVECs) (Breviario et al., [@B17]). The human PTX3 gene is located on chromosome 3q band 25, consists of 1861 base pairs, and is translated into 381 amino acids (Breviario et al., [@B17]). PTX3 belongs to the pentraxin family, which included the acute phase proteins C-reactive protein (CRP) and serum amyloid P-component (SAP). As PTX3 has a longer N-terminal domain, it is classified as a member of the long-pentraxin subfamily. Unlike the more common short pentraxins CRP and SAP, the *PTX3* gene is highly conserved across species (Garlanda et al., [@B38]). The *PTX3* gene consists of three exons, among which the first and second exons encode the signal sequence peptide and the N-terminal domain, and the third exon encodes the C-terminal domain. In the promoter region of the *PTX3* gene, a number of potential enhancer binding sequences (Pu-1, AP1, NF-κB, SP1, and NF-IL6) are located (He et al., [@B47]).

Structure
---------

After the processing of the signal sequence of the translated 1--17 amino acids, the mature PTX3 consists of two domains, i.e., the N-terminal domain (18--178 a.a.) and C-terminal domain (179--381 a.a.). The PTX3 C-terminal domain is a pentraxin-like domain, which is conserved among the pentraxin family with pentraxin signature (His-x-Cys-x-Ser/Thr-Trp-x-Ser). An N-linked glycosylation site (Asn220) is located in the C-terminal domain. In contrast to the C-terminal domain, the PTX3 N-terminal domain is a unique sequence unrelated to other proteins. The PTX3 protein forms an octamer via the inter-molecule disulfide bonds (Inforzato et al., [@B55], [@B52]). Briefly, the N-terminal domain participates in the organization of a tetramer, and the C-terminal domain participates in the dimerization of the tetramer. Interestingly, the N-terminal tetramer formation has two states; a tetramer via the inter-disulfide bonds or non-covalent dimerization of the inter-disulfide-bonded dimer. This results in the asymmetric form of the full-length PTX3 (Inforzato et al., [@B52]).

Expression pattern
------------------

PTX3 mRNA expression is induced by primary inflammatory signals in certain cells, such as myeloid dendritic cells (Doni et al., [@B36]), peripheral blood leukocytes (Alles et al., [@B2]), mononuclear macrophages/phagocytes (Alles et al., [@B2]; Goodman et al., [@B41]), vascular endothelial cells (Breviario et al., [@B17]; Lee et al., [@B71]), smooth muscle cells (Klouche et al., [@B63]), fibroblasts (Lee et al., [@B71]; Goodman et al., [@B41]), adipocytes (Abderrahim-Ferkoune et al., [@B1]), glial cells (Polentarutti et al., [@B93]), cumulus oophorus cells (Salustri et al., [@B103]), mesangial cells (Nauta et al., [@B86]), and synovial cells (Luchetti et al., [@B72]). Transcriptional activation of PTX3 in response to the pro-inflammatory cytokines TNFα and IL-1β is regulated by NF-κB binding site in the PTX3 promoter (Altmeyer et al., [@B3]; Basile et al., [@B9]). Other pathways also regulate PTX3 expression in a cell- and signal-dependent manner. In detail, please refer to the excellent reviews cited (He et al., [@B47]; Ortega-Hernandez et al., [@B89]; Deban et al., [@B28]; Inforzato et al., [@B53]).

The characteristic PTX3 expression pattern is observed in neutrophils. In mature neutrophils, the PTX3 protein is abundantly present in granules, but PTX3 mRNA expression is not detected. In contrast, PTX3 mRNA expression is observed in progenitor neutrophils, such as promyelocytes and myelocytes/metamyelocytes (Jaillon et al., [@B58]). As PTX3 protein expression is observed in both neutrophil precursors and mature neutrophils, it is considered that the PTX3 protein is produced during the course of neutrophil maturation and mature neutrophils store it for use-on-demand. Immunostaining revealed that PTX3 is present in neutrophil granules and that it colocalizes with lactoferrin (Jaillon et al., [@B58]; Savchenko et al., [@B104]), suggesting that PTX3 localizes to specific granules. The stored PTX3 in neutrophils is released upon *E. coli*, *S. aureus* or zymosan stimulation, as well as PMA, ionomycin or TNFα treatment (Jaillon et al., [@B58]; Savchenko et al., [@B104]; Daigo et al., [@B26]). PTX3 release is not induced by IL-1β or latex bead stimulation (Jaillon et al., [@B58]). The released PTX3 localizes to NETs and plays a non-redundant role in pathogen resistance. Thus, PTX3 in neutrophils plays a distinctive role in the innate immune response due to its rapid secretion, as well as by its unique pattern of ready-to-use expression and storage.

Circulating levels
------------------

As the pentraxins CRP and SAP are well-known acute phase proteins, PTX3 may also be an acute phase biomarker. Under physiological conditions, the circulating PTX3 level is as low as approximately 2 ng/mL (Yamasaki et al., [@B121]). Recently, many studies on the circulating PTX3 level in clinical trials have been reported. These reports indicate that the PTX3 levels are significantly increased in certain infectious, cardiovascular, kidney, and female reproductive system diseases as well as other disorders (summarized in Table [1](#T1){ref-type="table"}). In most cases, the PTX3 level correlates with both the severity and survivability of the disorder. In these diseases, the increases can reach up to 10\~100 times the control level in severe inflammatory and infectious diseases such as sepsis. In the case of sepsis, the plasma PTX3 dramatically increases to a level of up to 100 ng/mL (Muller et al., [@B83]) and the increase correlates with mortality (Mauri et al., [@B77]).

###### 

**Circulating PTX3 levels measurements in clinical trials**.

  **Disease category**                  **Diseases**                                                 **PTX3 concentration and significance**                                              **References**
  ------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------ ---------------------------
  Physiological level                                                                                2.00 (1.95, 2.04)[^a^](#TN1){ref-type="table-fn"}                                    Yamasaki et al., [@B121]
  Infectious diseases                   Systemic inflammatory response syndrome (SIRS)               SIRS: 28.0 ± 5.6 Control: 1.04 ± 0.09[^b^](#TN2){ref-type="table-fn"} *p* \< 0.005   Muller et al., [@B83]
                                        Pulmonary tuberculosis (TB)                                  TB: 3.21                                                                             Azzurri et al., [@B7]
                                                                                                     Control: 0.98[^c^](#TN3){ref-type="table-fn"} *p* \< 0.0001                          
                                        Sepsis                                                       Sepsis: 26 (1, 202)                                                                  Hill et al., [@B48]
                                                                                                     Control: 6 (1, 12)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001                      
                                        Febrile in the intensive/medium care unit (ICU/MC) or ward   In ICU/MC: 44.4 (13.6, 105.9)                                                        De Kruif et al., [@B31]
                                                                                                     In ward: 14.2 (7.01, 25.1)                                                           
                                                                                                     Control: 2.30 (1.66, 3.67)[^d^](#TN4){ref-type="table-fn"} *p* = 0.01                
                                        Bacteremia                                                   Non-survivor: 44.8 (10.7, 69.4)                                                      Huttunen et al., [@B50]
                                                                                                     Survivor: 6.4 (3.4, 13.5)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001               
  Cardiovascular diseases               Unstable angina pectoris (UAP)                               UAP: 6.09 (4.34--7.85)                                                               Inoue et al., [@B56]
                                                                                                     Control: 2.30 (2.03--2.55)[^e^](#TN5){ref-type="table-fn"} *p* = 0.00003             
                                        Chronic heart failure (CHF)                                  CHF: 3.06 (2.38, 4.23)                                                               Kotooka et al., [@B65]
                                                                                                     Control: 1.91 (1.35, 2.60)[^d^](#TN4){ref-type="table-fn"} *p* = 0.001               
                                                                                                     Cardiac event: 6.0 (4.3, 9.3)                                                        Ishino et al., [@B57]
                                                                                                     Event-free: 3.2 (2.0, 5.5)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001              
                                        Heart failure (HF)                                           Cardiac event: 6.22 (5.59)                                                           Suzuki et al., [@B114]
                                                                                                     Event-free: 2.99 (2.95)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001                 
                                                                                                     HF: 3.28 (1.51, 2.90)                                                                Matsubara et al., [@B76]
                                                                                                     Non-HF: 2. 18 (1.51, 2.90)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001              
                                        Coronary artery disease (CAD)                                CAD with inflammatory rheumatic disease (IRD): 1.96 ± 0.98                           Hollan et al., [@B49]
                                                                                                     Control: 1.21 ± 0.59[^b^](#TN2){ref-type="table-fn"} *p* \< 0.001                    
                                        Aortic valve stenosis (AS)                                   AS: 3.5 ± 1.9                                                                        Naito et al., [@B84]
                                                                                                     Control: 2.1 ± 0.8[^b^](#TN2){ref-type="table-fn"} *p* \< 0.05                       
                                        Acute coronary syndrome (ACS)                                ACS: 1.73 ± 0.82                                                                     Ustundag et al., [@B117]
                                                                                                     Control: 0.50 ± 0.39[^b^](#TN2){ref-type="table-fn"} *p* \< 0.001                    
                                                                                                     ACS: 0.36 (0.225, 1.39)                                                              Kume et al., [@B66]
                                                                                                     Control: 0.015 (0, 0.06)[^f^](#TN6){ref-type="table-fn"} *p* \< 0.0001               
                                        Hypertension                                                 Anti-hypertensive mediation                                                          Parlak et al., [@B90]
                                                                                                     Pre-treatment: 35.25 ± 5.45                                                          
                                                                                                     Post-treatment: 0.14 ± 0.19[^b^](#TN2){ref-type="table-fn"} *p* \< 0.0001            
                                        Acute ischemic strokes                                       Non-survivor: 18.0 (8.2, 26.1)                                                       Ryu et al., [@B101]
                                                                                                     Survivor: 6.4 (3.4, 11.8)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001               
                                        Giant cell arteritis (GCA)                                   GCA: 23.31 ± 4.06                                                                    Baldini et al., [@B8]
                                                                                                     Control: 3.97 ± 0.28[^g^](#TN7){ref-type="table-fn"} *p* \< 0.003                    
  Kidney diseases                       Hemodialysis (HD)                                            HD: 3.03 ± 1.81                                                                      Malaponte et al., [@B74]
                                                                                                     Uremic patients: 2.34 ± 1.19                                                         
                                                                                                     Control 1.03 ±0.4[^b^](#TN2){ref-type="table-fn"} *p* \< 0.001                       
                                                                                                     HD: 1.87 (1.34, 2.50)                                                                Xu et al., [@B120]
                                                                                                     Control: 1.11 (0.86, 1.51)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001              
                                                                                                     Renal transplant patients: 5.78 (1.09--20.36)                                        Argani et al., [@B5]
                                                                                                     HD group: 1.65 (0.24--7.89)[^h^](#TN8){ref-type="table-fn"} *p* = 0.0001             
                                        Chronic kidney disease (CKD)                                 Stage 5 CKD: 5.7 (0.9, 64.3)                                                         Tong et al., [@B115]
                                                                                                     Stage 3 to 4 CKD: 2.2 (0.4, 16.0)                                                    
                                                                                                     Control: 1.8 (0.1, 9.1)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001                 
                                                                                                     Stage 5 CKD: 5.3 (1.0, 58.0)                                                         Suliman et al., [@B113]
                                                                                                     Control: 1.8 (0.1, 9.2)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001                 
                                                                                                     CKD: 7.7 (1.8, 32.9)                                                                 Yilmaz et al., [@B122]
                                                                                                     Control: 1.3 (0.1, 2.7)[^f^](#TN6){ref-type="table-fn"} *p* \< 0.001                 
                                                                                                     CKD: 3.80 ± 2.35                                                                     Nishi et al., [@B87]
                                                                                                     Control: 2.15 ± 0.93[^b^](#TN2){ref-type="table-fn"} *p* \< 0.0001                   
                                                                                                     CKD with periodontitis: 6.3380 ± 2.74875                                             Pradeep et al., [@B94]
                                                                                                     CKD: 5.4100 ± 2.65296                                                                
                                                                                                     Healthy: 1.8350 ± 0.75977[^b^](#TN2){ref-type="table-fn"} *p* = 0.000                
  Female reproductive system diseases   Preeclampsia (PE)                                            PE: 13.8 (3.9, 32.3)                                                                 Cetin et al., [@B21]
                                                                                                     Control: 2.2 (1.2, 3.8)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001                 
                                                                                                     PE: 22.64 (18.56, 26.34)                                                             Hamad et al., [@B44]
                                                                                                     Control: 13.17 (8.55, 16.54)[^d^](#TN4){ref-type="table-fn"} *p* \< 0.001            
                                        Pelvic inflammatory disease (PID)                            PID: 9.3 ± 1.01                                                                      Chang et al., [@B22]
                                                                                                     Control: 2.27 ± 0.12[^b^](#TN2){ref-type="table-fn"} *p* \< 0.001                    
                                        Polycystic ovary syndrome (PCOS)                             PCOS: 1.0 ± 3.6                                                                      Aydogdu et al., [@B6]
                                                                                                     Control: 0.8 ± 0.8[^b^](#TN2){ref-type="table-fn"} *p* = 0.021                       
  Others                                Severe Psoriasis (sP)                                        sP: 2.84 ± 0.94                                                                      Bevelacqua et al., [@B12]
                                                                                                     Control: 1.22 ± 0.47[^b^](#TN2){ref-type="table-fn"} *p* \< 0.0001                   
                                        Ulcerative colitis (UC) and crohn\'s disease (CD)            Active UC: 8.22 ± 5.48                                                               Kato et al., [@B61]
                                                                                                     Active CD: 5.80 ± 3.59                                                               
                                                                                                     Control: 1.76 ± 1.02[^b^](#TN2){ref-type="table-fn"} *p* \< 0.05                     
                                        Obesity                                                      Obesity: 0.99 ± 0.09                                                                 Miyaki et al., [@B81]
                                                                                                     Control: 0.63 ± 0.05[^g^](#TN5){ref-type="table-fn"} *p* \< 0.01                     
                                        Central obesity in abdominal obesity patients                Central obesity: 3.00 ± 2.61                                                         Shim et al., [@B107]
                                                                                                     Control: 1.33 ± 0.81[^b^](#TN5){ref-type="table-fn"} *p* \< 0.01                     
                                        Severe traumatic brain injury (TBI)                          non-survivors 9.95 (6.42)                                                            Gullo Jda et al., [@B43]
                                                                                                     Survivors 5.46 (4.87)[^b^](#TN2){ref-type="table-fn"} μg/mL *p* \< 0.001             
                                        Obstructive sleep apnea (OSA)                                Moderate-to severe OSA: 2.36 (1.79, 2.98)                                            Kasai et al., [@B60]
                                                                                                     Control: 1.53 (1.14, 2.04)[^f^](#TN6){ref-type="table-fn"} *p* \< 0.01               
                                        Schizophrenia (SZ)                                           SZ with the metabolic syndrome: 388.2 (504.1)                                        Beumer et al., [@B11]
                                                                                                     SZ: 430.4 (523.0)                                                                    
                                                                                                     Control: 213.6 (524.0)[^d^](#TN4){ref-type="table-fn"} pg/mL *p* \< 0.001            

PTX3 concentrations are shown in ng/mL, unless indicated.

Geometrical mean (confidence interval).

Mean ± SD.

Geometrical mean.

Median (interquartile range).

Mean (95% confidence interval).

Median (25th percentile, 75th percentile).

Mean ± SEM.

Median (Minimum-Maximum).

Although not included in Table [1](#T1){ref-type="table"}, there are other infectious diseases, such as severe dengue virus infection (Mairuhu et al., [@B73]) and meningococcal disease (Sprong et al., [@B111]), in which the PTX3 levels are also increased. The PTX3 plasma concentration is increased in patients with acute myocardial infarction (Peri et al., [@B91]). During pregnancy, the serum PTX3 level slightly increases as the pregnancy progresses (Larsson et al., [@B67]). A higher PTX3 level is observed in preeclampsia (Cetin et al., [@B21]; Rovere-Querini et al., [@B99]). Finally, the serum PTX3 level is reported to be a biomarker for lung carcinoma (Diamandis et al., [@B32]). Thus, the circulating PTX3 level increases non-specifically in various infections and inflammatory disorders. For the purpose of diagnostic measurement, the dynamics of the PTX3 complex, such as the NET component proteins should be monitored (more details are discussed below).

Function
--------

PTX3 has been postulated to play a variety of roles in innate immunity, inflammatory regulation, and female fertility (Bottazzi et al., [@B13]; Garlanda et al., [@B40]; Inforzato et al., [@B53]; Cieslik and Hrycek, [@B24]). PTX3-knockout and transgenic mice studies have indicated that the predominant role of PTX3 occurs in host protection in the case of lung injury, infection, vascular damage, as well as certain other disorders (summarized in Table [2](#T2){ref-type="table"}). Briefly, the resistance against pathogens such as *Aspergillus fumigatus*, *Paracoccidioides brasiliensis*, and *Klebsiella pneumoniae* has been reported (Garlanda et al., [@B39]; Diniz et al., [@B34]; Soares et al., [@B108]). In addition to its anti-pathogenic activity, PTX3 also has been shown to play a role in protecting against severe inflammatory reactions in animal models of sepsis (Dias et al., [@B33]), seizure-induced neurodegeneration (Ravizza et al., [@B96]) and acute myocardial infarction (Salio et al., [@B102]). In addition, PTX3 participates in extracellular matrix deposition. PTX3 is involved in the organization of hyaluronan in the viscoelastic matrix of cumulus oophorus (Scarchilli et al., [@B105]). It is considered that these functions of PTX3 are exhibited synergistically along with the binding of specific ligands (the details are provided in section "Ligands").

###### 

**Responses to certain disorders in PTX3-knockout and PTX3-transgenic mice**.

  **Category**      **Experiment summary**                                                    **Result summary**                                                                           **References**
  ----------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------
  Lung injury       Murine hepatitis virus strain 1 (MHV-1) infection                         Causing greater severity of acute lung injury (ALI)[^a^](#TN10){ref-type="table-fn"}         Han et al., [@B46]
                    Ventilator-induced lung injury (VILI)                                     Faster development of VILI[^b^](#TN11){ref-type="table-fn"}                                  Real et al., [@B98]
                    LPS instillation                                                          Causing greater severity of ALI[^a^](#TN10){ref-type="table-fn"}                             Han et al., [@B45]
  Vascular damage   Coronary artery ligation and reperfusion                                  Worsen heart damage[^a^](#TN10){ref-type="table-fn"}                                         Salio et al., [@B102]
                    Atherogenic diet feed                                                     Increased atherosclerotic lesion area in PTX3 and ApoE-double KO mice                        Norata et al., [@B88]
                    Ischemia and reperfusion of the superior mesenteric artery                Prevent tissue injury and mortality[^a^](#TN10){ref-type="table-fn"}                         Souza et al., [@B109]
                                                                                              Increased tissue injury and mortality[^b^](#TN11){ref-type="table-fn"}                       Souza et al., [@B110]
  Infection         LPS-induced endotoxemia                                                   Increased survival ratio[^b^](#TN11){ref-type="table-fn"}                                    Dias et al., [@B33]
                    CLP-induced sepsis                                                        Increased survival ratio[^b^](#TN11){ref-type="table-fn"}                                    Dias et al., [@B33]
                    Pulmonary infection by *Aspergillus fumigatus*                            Decreased survival ratio[^a^](#TN10){ref-type="table-fn"}                                    Garlanda et al., [@B39]
                    Pulmonary infection by *Klebsiella pneumoniae*                            Faster lethality by a high inoculum administration[^b^](#TN11){ref-type="table-fn"}          Soares et al., [@B108]
                                                                                              Delayed lethality by a mid-to-low inoculum administration[^b^](#TN11){ref-type="table-fn"}   Soares et al., [@B108]
                    Murine cytomegalovirus (MCMV) infection                                   More susceptible to MCMV infection[^a^](#TN10){ref-type="table-fn"}                          Bozza et al., [@B15]
                    Influenza virus infection                                                 More susceptible to influenza virus infection[^a^](#TN10){ref-type="table-fn"}               Reading et al., [@B97]
  Others            Fas-deficient (lpr) C57BL/6 (B6) mice with mild lupus-like autoimmunity   Aggravate autoimmune lung disease in PTX3-KO B6^Lpr^ mice                                    Lech et al., [@B70]
                    Kidney ischemia reperfusion injury                                        Less kidney injury and inflammation[^a^](#TN10){ref-type="table-fn"}                         Chen et al., [@B23]
                    Subcutaneous injection of Matrigel containing FGF2 and/or TSG-6           Abolishing of vascularization inhibition in PTX-KO mice                                      Leali et al., [@B69]
                    Rolling interaction of PMNs in the mesenteric venules                     Increased rolling interaction frequency[^a^](#TN10){ref-type="table-fn"}                     Deban et al., [@B30]
                    Sexual system                                                             Subfertile[^a^](#TN10){ref-type="table-fn"}                                                  Varani et al., [@B118]
                    Kainate-induced seizures                                                  More widespread seizure-related neuronal damage in the forebrain of PTX3-KO mice             Ravizza et al., [@B96]

PTX3-knockout mouse study.

PTX3-transgenic mouse study.

Of note, among the studies in PTX3-knockout and transgenic mice, there are some reports of an opposite effect of PTX3 on host-protection. In an intestinal ischemia and reperfusion model, Souza et al. reported an increased injury and lethality in the PTX3-transgenic mice that seemed to be associated with elevation of the TNFα concentration and aggravation of the inflammatory response (Souza et al., [@B110]). They also reported the suppression of tissue injury and lethality after ischemic and reperfusion in PTX3-knockout mice. PTX3 administration to these PTX3-knockout mice reversed this suppression (Souza et al., [@B109]). Other groups have also reported an adverse effect of PTX3 in acute ischemic lung injury (Chen et al., [@B23]) and ventilator-induced lung injury (Real et al., [@B98]). In the case of *Klebsiella pneumoniae* infection, faster lethality was observed when a higher inoculum was administered to PTX3-transgenic mice, but the lethality was conversely delayed when a middle or low inoculum was administered (Soares et al., [@B108]). Taking these bi-phasic functions of PTX3 in host-defense into account, more detailed accounts of the disease-specific mechanisms of PTX3 need to be elucidated to achieve useful clinical applications.

Ligands
-------

The multiple host-protective functions of PTX3 arise from the capacity for the recognition and binding to ligands. The reported PTX3 ligands are classified as follows: (1) complement components; (2) Fungi, bacteria, microbial components, and viruses; (3) selectin P; (4) extracellular matrix proteins and (5) growth factors (Presta et al., [@B95]; Mantovani et al., [@B75]; Deban et al., [@B27]; Moalli et al., [@B82]). Some of these ligands bind to PTX3 in a PTX3-domain specific manner, while others require full-length PTX3 for binding (Deban et al., [@B27]; Bottazzi et al., [@B14]).

1.  PTX3 binds to certain select complement components, such as C1q (Inforzato et al., [@B54]), C4b-binding proteins (Braunschweig and Józsi, [@B16]), ficolins (Ma et al., [@B78]; Gout et al., [@B42]), mannose-binding lectin 2 (MBL) (Ma et al., [@B79]), factor H (Deban et al., [@B29]; Kopp et al., [@B64]), factor H-like protein 1 (Kopp et al., [@B64]) and factor H-related protein 1 (Kopp et al., [@B64]) for the regulation of the complement pathways in the innate immune response. The interaction of PTX3 and C1q elicits a dual consequence in the classical complement pathway. When C1q binds to immobilized PTX3, the classical complement pathway is activated; however, the binding of C1q to PTX3 in the fluid phase inhibits complement activation (Nauta et al., [@B85]). PTX3 can also activate the lectin pathway by binding to the ficolins and MBL. PTX3 enhances complement deposition by ficolin-2 on the *Aspergillus fumigatus* surface (Ma et al., [@B78]), and PTX3-MBL binding enhanced C4 and C3 deposition as well as the phagocytosis of *Candida albicans* (Ma et al., [@B79]). PTX3 is not only involved in complement activation, but also acts as a complement inhibitor to regulate excessive complement activation by binding to C4b-binding proteins and factor H. Please refer to the review by Doni et al. for more detail (Doni et al., [@B35]).

2.  In the protection afforded against infection, PTX3 recognizes certain fungi, bacteria, microbial moieties, and viruses. PTX3 binds to microbial pathogens such as *Pseudomonas aeruginosa* (Garlanda et al., [@B39]), *Salmonella typhimurium* (Garlanda et al., [@B39]), *Aspergillus fumigatus* (Garlanda et al., [@B39]), and *Paracoccidioides brasiliensis* (Diniz et al., [@B34]). PTX3-knockout mice are susceptible to invasive pulmonary aspergillosis due to inappropriate Th1 and Th2-helper-cell-mediated resistance (Garlanda et al., [@B39]). Macrophages from PTX3-transgenic mice exhibit improved phagocytosis of *Paracoccidioides brasiliensis* as well as an enhancement of the production of nitric oxide (NO) (Diniz et al., [@B34]). PTX3 also binds to outer membrane protein A from *Klebsiella pneumoniae* (KpOmpA) in order to modulate the inflammatory response triggered by KpOmpA (Jeannin et al., [@B59]). PTX3 binds to cytomegalovirus and influenza virus type A for the inhibition of infection (Bozza et al., [@B15]; Reading et al., [@B97]). Upon binding to influenza virus, PTX3 exerts anti-viral activity by the inhibition of hemagglutination, the neutralization of virus infectivity and the inhibition of viral neuraminidase (Reading et al., [@B97]).

3.  As an inflammatory modulator, PTX3 binds to selectin P. The N-linked glycosidic moiety of PTX3 contributes to the binding of selectin P, and this binding dampens neutrophil recruitment at the sites of inflammation (Deban et al., [@B30]). Importantly, in a model of acid-induced acute lung injury, both exogenous PTX3 and endogenously released PTX3 administration suppress neutrophil recruitment (Deban et al., [@B30]). This suggests a negative feedback role of PTX3 that dampens the excessive neutrophil recruitment via selectin P.

4.  PTX3 takes part in extracellular matrix formation by binding to TNFα-induced protein 6 (TNFAIP6 or TSG-6) and inter-α-trypsin inhibitor (Iα I) (Salustri et al., [@B103]; Scarchilli et al., [@B105]; Ievoli et al., [@B51]). PTX3-knockout mice exhibit a defect in female fertility because of the defects in ovulation (Varani et al., [@B118]) and the organization of the cumulus oophorus extracellular matrix (Salustri et al., [@B103]). The PTX3-TSG-6 and PTX3-Iα I binding events are considered to be essential for the organization of hyaluronan in the viscoelastic matrix of cumulus oophorus (Inforzato et al., [@B53]; Moalli et al., [@B82]).

5.  PTX3 binding to fibroblast growth factor 2 (FGF-2) regulates endothelial cell proliferation and angiogenesis, smooth muscle cell (SMC) activation, and intima thickening after arterial injury (Rusnati et al., [@B100]; Camozzi et al., [@B20]). PTX3-FGF2 binding can inhibit the proliferation and chemotactic activity of FGF2 in SMCs by interfering with the interaction of the FGF2 and FGF receptors (Camozzi et al., [@B20]).

Taking these results, it is clear that the protective effects of PTX3 are realized in coordination with specific PTX3 ligands. Therefore, we carried out a proteome-wide identification of PTX3 ligands and complexes in septic patient serum and plasma. PTX3 and its complex component proteins were immunoprecipitated by anti-PTX3 antibody-crosslinked magnetic beads, and the isolated fractions were subjected to shotgun proteomics analysis for label-free relative quantitation via spectral counting (Daigo et al., [@B26]). The identified proteins included the known PTX3 ligands such as C1q, ficolins, TSG-6, and Iα I, as mentioned above. Additionally, the ficolin-binding proteins of mannan-binding lectin serine protease 1 and 2 (MASP1 and MASP2) (Ma et al., [@B78]), and the TSG-6 binding proteins of the versican core protein (VCAN) and thrombospondin-1 (THBS1) (Salustri et al., [@B103]) were included in the proteins that were identified. As these proteins were identified in pooled normal human plasma with artificially spiked recombinant PTX3, these appear to be stable circulating PTX3 complexes. Nevertheless, the disease-specific dynamics of these binding levels need to be investigated further, as do the specific functions of these PTX3 complexes in sepsis.

NET component proteins as PTX3 ligands: a newly recognized protective role
==========================================================================

In the effort to identify the PTX3 ligand in septic patient fluids, a novel finding is that the NET component proteins were included (Daigo et al., [@B26]) (Table [3](#T3){ref-type="table"}). A detailed investigation revealed that azurocidin 1 (AZU1) and myeloperoxidase (MPO) directly bind to PTX3. AZU1 and MPO belong to the NET component proteins (Urban et al., [@B116]) and exert bactericidal activity (Watorek, [@B119]; Klebanoff, [@B62]). AZU1 preferably binds to the PTX3 N-terminal domain, with a pattern of calcium ion dependency. In contrast to AZU1, MPO binds to both the PTX3 N-terminal and C-terminal domains, and does not require calcium ions. Further investigation of the PTX3-AZU1 interaction revealed that the AZU1 binding affinity to PTX3 was 22 ± 7.6 nM, and that AZU1 and PTX3 are partially co-localized in NETs (Daigo et al., [@B26]).

###### 

**List of the NET component proteins and proteins belonging to the PTX3 complex**.

  **NET component proteins**   **Proteomic identification of PTX3 complex in sepsis**                  
  ---------------------------- -------------------------------------------------------- -------------- ----------------
  Granules                     Neutrophil elastase                                      ELANE          
                               Lactotransferrin                                         LTF            
                               Azurocidin                                               AZU1           Yes
                               Cathepsin G                                              CTSG           
                               Myeloperoxidase                                          MPO            Yes
                               Proteinase 3                                             PRTN3          
                               Lysozyme C                                               LYZ            
                               Neutrophil defensin 1 and 3                              DEFA1 and 3    Yes (DEFA1)
                               Pentraxin 3                                              PTX3           Target protein
                               Bactericidal permeability-increasing protein             BPI            
                               Cathelicidin anti-microbial peptide                      CAMP           
  Nucleus                      Histone H1                                               H1F0           
                               Histone H2A                                              H2A            Yes
                               Histone H2B                                              H2B            
                               Histone H2B-like                                         H2B            
                               Histone H3                                               H3             Yes
                               Histone H4                                               H4             Yes
                               Myeloid cell nuclear differentiation antigen             MNDA           
  Cytoplasm                    S100 calcium-binding protein A8                          S100A8         
                               S100 calcium binding protein A9                          S100A9         
                               S100 calcium-binding protein A12                         S100A12        
  Cytoskeleton                 Actin (beta and/or gamma 1)                              ACTB, ACTG1    Yes
                               Myosin-9                                                 MYH9           Yes
                               Alpha-actinin (1 and/or -4)                              ACTN1, ACTN4   
                               Plastin-2                                                LCP1           
                               Cytokeratin-10                                           KRT10          Yes
  Peroxisomal                  Catalase                                                 CAT            
  Glycolytic enzymes           Alpha-enolase                                            ENO1           Yes
                               Transketolase                                            TKT            Yes

From these results, it is suggested that PTX3 may enhance the bactericidal efficiency of AZU1 and MPO in terms of both pathogen recognition and AZU1 and MPO binding (Figure [1](#F1){ref-type="fig"}). The mechanism by which PTX3 localizes in NETs has not yet been determined, but it is possible that PTX3 localization arises from an interaction with histones or the basic proteins AZU1, MPO, and defensin, along with a simultaneous association between these basic proteins and DNA (Figure [1](#F1){ref-type="fig"}). It is not clear at present whether the PTX3-AZU1 and PTX3-MPO binding events in the bloodstream take place within or outside of NETs. Either or even both of these are possible, and these complexes may be active in pathogen recognition and also involved in clearance. In septic patients, the plasma levels of AZU1 are increased, but do not significantly correlate with mortality (Berkestedt et al., [@B10]). As useful biomarkers of sepsis not yet available (Pierrakos and Vincent, [@B92]), the binding levels of PTX3-AZU1 and PTX3-MPO in septic plasma have the important potential to fulfill this purpose.

![**Schematic relationship and role of PTX3 and NET component proteins in pathogen recognition and clearance.** NET component proteins which were identified as PTX3 complex (Daigo et al., [@B26]) are associated PTX3 in NETs. Among these, the confirmed direct interaction of AZU1 and MPO to PTX3, and formerly reported histone-PTX3 interaction (Garlanda et al., [@B38]) are designated by two-way arrows. These bindings facilitate pathogen clearance efficiency of AZU1 and MPO. The pathogen recognition and anti-pathogenic action are designated by open arrow and closed arrow in box, respectively. Two-way arrows with dashed lines designate other potential interactions to PTX3. The indirect association to DNA via histone or basic proteins such as DEFA1, AZU1, and MPO, which DNA associations are designated by dashed lines, maintains PTX3 localization in NETs. PTX3, pentraxin 3; DEFA1, neutrophil defensin 1; MYH9, Myosn-9; KRT10, Cytokeratin-10; AZU1, azurocidin 1; MPO: myeloperoxidase.](fimmu-03-00378-g0001){#F1}

Conclusion {#s2}
==========

Recent proteomic investigation of the circulating PTX3 complex components has revealed new and pivotal roles of PTX3 in the innate immune response, along with a pattern of binding to the NET component proteins. In NETs, PTX3 brings the NET component proteins into close proximity with the pathogens that PTX3 capture in order to enhance pathogen clearance. Also, in the bloodstream, PTX3 forms a complex with bactericidal proteins for the recognition and clearance of pathogens. These activities of PTX3 in concert contribute to the host-protective effect. In addition, the dynamic changes that occur in PTX3 and its complex proteins may become specific biomarker for severe inflammatory diseases.
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